Spineart Receives FDA Approval for BAGUERA® C Cervical Disc for 1 and 2 Contiguous Levels

Spineart announced that its BAGUERA® C cervical disc has received FDA approval for use in 1 and 2 contiguous levels, expanding access in the United States to a motion-preserving solution for patients with cervical disc disease. The approval is supported by nearly two decades of international clinical experience and two randomized controlled trials.